BACKGROUND: Rheumatoid arthritis (RA) is a connective tissue disorder (CTD) associated with an increased risk of malignancy including lung cancer (LC). METHODS: Clinicopathologic characteristics of LC patients with RA and without systemic CTD were compared to identify the potential differences. A further intra-group comparison was conducted in LC patients with RA according to smoking status to explore the effect of smoking on the clinicopathologic characteristics of LC patients with RA. RESULTS: A total of 44 LC patients with RA and 176 LC patients without systemic CTD were included in this study. There were no statistically significant differences in the distribution of age, gender, smoking status, histology type, and tumor location between the two groups. However, a significantly larger proportion of patients with stage IV LC was noted in LC with RA group (59.1% vs. 39.2%, P=0.017). Besides, more LC patients with RA had an Eastern Cooperative Oncology Group (ECOG) performance score (PS) ≥2 (8.0% vs. 20.5%, P=0.015). On multivariate analysis, tumor stage (OR: 1.41, 95% CI: 1.23-13.70, P=0.021) and presence of RA (OR: 1.35, 95% CI: 1.34-11.16, P=0.012) demonstrated independent associations with poorer ECOG PS. RA-interstitial lung disease (RA-ILD) was observed in 18 LC patients (40.9%) with RA. Among them, usual interstitial pneumonia (UIP) was observed only in past or current smokers, whereas non-specific interstitial pneumonia (NSIP) was observed only in non-smokers. CONCLUSIONS: There were no statistically significant differences in the distribution of age, gender, smoking status, histology type, and tumor location between LC patients with RA and those without systemic CTD. Compared with LC patients without CTD, LC patients with RA were more likely to be diagnosed at an advanced stage and have a poorer ECOG PS score, and were less likely to receive surgery, radiotherapy, chemotherapy and targeted therapy.
BACKGROUND: Rheumatoid arthritis (RA) is a connective tissue disorder (CTD) associated with an increased risk of malignancy including lung cancer (LC). METHODS: Clinicopathologic characteristics of LC patients with RA and without systemic CTD were compared to identify the potential differences. A further intra-group comparison was conducted in LC patients with RA according to smoking status to explore the effect of smoking on the clinicopathologic characteristics of LC patients with RA. RESULTS: A total of 44 LC patients with RA and 176 LC patients without systemic CTD were included in this study. There were no statistically significant differences in the distribution of age, gender, smoking status, histology type, and tumor location between the two groups. However, a significantly larger proportion of patients with stage IV LC was noted in LC with RA group (59.1% vs. 39.2%, P=0.017). Besides, more LC patients with RA had an Eastern Cooperative Oncology Group (ECOG) performance score (PS) ≥2 (8.0% vs. 20.5%, P=0.015). On multivariate analysis, tumor stage (OR: 1.41, 95% CI: 1.23-13.70, P=0.021) and presence of RA (OR: 1.35, 95% CI: 1.34-11.16, P=0.012) demonstrated independent associations with poorer ECOG PS. RA-interstitial lung disease (RA-ILD) was observed in 18 LC patients (40.9%) with RA. Among them, usual interstitial pneumonia (UIP) was observed only in past or current smokers, whereas non-specific interstitial pneumonia (NSIP) was observed only in non-smokers. CONCLUSIONS: There were no statistically significant differences in the distribution of age, gender, smoking status, histology type, and tumor location between LC patients with RA and those without systemic CTD. Compared with LC patients without CTD, LC patients with RA were more likely to be diagnosed at an advanced stage and have a poorer ECOG PS score, and were less likely to receive surgery, radiotherapy, chemotherapy and targeted therapy.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Martina Bonifazi; Irene Tramacere; Giovanni Pomponio; Barbara Gabrielli; Enrico V Avvedimento; Carlo La Vecchia; Eva Negri; Armando Gabrielli Journal: Rheumatology (Oxford) Date: 2012-11-22 Impact factor: 7.580
Authors: Rachelle Buchbinder; Melissa Barber; Louise Heuzenroeder; Anita E Wluka; Graham Giles; Stephen Hall; Andrew Harkness; Daniel Lewis; Geoff Littlejohn; Marian H Miller; Peter F J Ryan; Damien Jolley Journal: Arthritis Rheum Date: 2008-06-15
Authors: Dong Won Park; Jiin Choi; Sung Jun Chung; Tai Sun Park; Hyun Lee; Ji-Yong Moon; Sang-Heon Kim; Tae-Hyung Kim; Ho Joo Yoon; Jang Won Sohn Journal: Transl Cancer Res Date: 2020-04 Impact factor: 1.241